PREVIEW-Astra, Boehringer may steal show at heart congress
* AstraZeneca's Brilinta vies for Plavix market share
* Boehringer's Pradaxa aims to replace warfarin
* New drugs competitors for Eli Lilly, Bayer
* Clinical data due Aug. 30 in Barcelona
By Ben Hirschler, European Pharmaceuticals Correspondent
LONDON, Aug 24 (Reuters) - The sickly pharmaceuticals sector could get a shot in the arm next weekend if two new heart drugs from Anglo-Swedish AstraZeneca (AZN.L: Quote, Profile, Research) and unlisted German group Boehringer Ingelheim live up to expectations.
AstraZeneca aims to show at a big cardiology congress in Barcelona that its experimental blood thinner Brilinta has a clear edge over Sanofi-Aventis (SASY.PA: Quote, Profile, Research) and Bristol-Myers Squibb's (BMY.N: Quote, Profile, Research) Plavix, while Boehringer will showcase Pradaxa.
In both cases, billions of dollars are at stake. Continued...
Economy seen growing at 7.2 pct in FY10 - govt
The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget. Full Article
Greek crisis sets euro zone enlargement back
The Greek debt crisis has dealt a setback to prospects of enlarging the euro zone by highlighting the difficulties of managing the single currency area. Full Article
India
US
UK
